Lilly Closes AtaiBeckley Deal to Push Rapid-Acting Depression Drugs
Eli Lilly has closed its purchase of AtaiBeckley, folding a clinical-stage mental-health pipeline into Lilly Neuroscience. The 11 September 2026 close turns a July agreement into an owned asset: rapid-acting neuroplastogen programs aimed at treatment-resistant depression and related conditions, rather than another chronic daily pill franchise. What happened Lilly announced completion of the acquisition of […]